Guardant Health, Inc.(GH)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
GH | 21.82 B | - | 44.30% | -38.33% | -$3.50 | - | - | 0.00% | $191.05 | $66.59 |
CVS | 121.18 B | 24.93x | 7.10% | 1.18% | $3.80 | 6.21% | 0.95x | 2.81% | $110.00 | $68.48 |
CI | 81.02 B | 12.67x | 6.70% | 2.27% | $24.19 | 16.76% | 0.74x | 2.00% | $307.00 | $234.20 |
LH | 26.21 B | 26.73x | 5.80% | 6.99% | $12.09 | 11.73% | 0.79x | 0.89% | $341.07 | $242.07 |
DGX | 26.17 B | 25.17x | 10.20% | 9.19% | $9.42 | 14.60% | 0.81x | 1.40% | $247.92 | $168.35 |
Peer Valuation & Performance Analysis
Peer group analysis for Guardant Health, Inc. (GH) compared to its primary competitors (including CVS, CI, LH) reveals distinct metrics. GH trades at a valuation discount relative to its competitors, with a P/E ratio of -46.5x versus the peer average of 22.4x (representing a 308% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, GH's revenue growth of 44.3% exceeds the peer average of 7.5%, highlighting its competitive strength and market share gains. Additionally, its net margin of -38.3% is below the peer average of 4.9%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• GH ranks #0 in P/E ratio, #1 in revenue growth, and #5 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $158.00 | $163.56 | $155.07 | $162.59 | 1,308,529 | +2.98% |
| 2026-10-19 | $160.65 | $163.91 | $155.00 | $157.88 | 1,869,700 | -0.45% |
| 2026-10-16 | $165.88 | $168.47 | $157.44 | $158.60 | 1,975,600 | -4.39% |
| 2026-10-15 | $160.78 | $168.86 | $159.00 | $165.88 | 1,329,000 | +1.77% |
| 2026-10-14 | $159.89 | $166.16 | $159.00 | $162.99 | 1,278,800 | +0.56% |
| 2026-10-13 | $161.95 | $164.53 | $158.36 | $162.09 | 1,297,300 | -0.43% |
| 2026-10-12 | $168.26 | $168.69 | $158.46 | $162.79 | 1,556,100 | -2.79% |
| 2026-10-09 | $166.03 | $170.81 | $166.03 | $167.47 | 1,519,900 | +1.15% |
| 2026-10-08 | $166.24 | $167.28 | $161.61 | $165.56 | 1,599,400 | -1.65% |
| 2026-10-07 | $166.50 | $171.55 | $165.00 | $168.33 | 2,200,600 | -1.38% |
| 2026-10-06 | $188.00 | $191.05 | $170.05 | $170.69 | 3,386,200 | -8.83% |
| 2026-10-05 | $177.45 | $187.69 | $176.37 | $187.22 | 1,738,400 | +5.30% |
| 2026-10-02 | $173.32 | $179.17 | $172.00 | $177.80 | 1,650,700 | +1.75% |
| 2026-10-01 | $177.17 | $180.91 | $173.96 | $174.75 | 1,961,100 | -2.02% |
| 2026-09-30 | $177.75 | $180.34 | $175.33 | $178.36 | 1,576,200 | +0.35% |
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.